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Atypical antipsychotic drugs, such as clozapine and
risperidone, have a high affinity for the serotonin
5-HT2A G protein-coupled receptor (GPCR), the
2AR, which signals via a Gq heterotrimeric G protein.
The closely related non-antipsychotic drugs, such as
ritanserin and methysergide, also block 2AR func-
tion, but they lack comparable neuropsychological
effects. Why some but not all 2AR inhibitors exhibit
antipsychotic properties remains unresolved. We
now show that a heteromeric complex between
the 2AR and the Gi-linked GPCR, metabotropic
glutamate 2 receptor (mGluR2), integrates ligand
input, modulating signaling output and behavioral
changes. Serotonergic and glutamatergic drugs
bind the mGluR2/2AR heterocomplex, which then
balances Gi- and Gq-dependent signaling. We find
that the mGluR2/2AR-mediated changes in Gi and
Gq activity predict the psychoactive behavioral
effects of a variety of pharmocological compounds.
These observations provide mechanistic insight
into antipsychotic action that may advance thera-
peutic strategies for disorders including schizo-
phrenia and dementia.INTRODUCTION
G protein-coupled receptors (GPCRs) are the most common
cellular targets for drugs used in the clinic (Rosenbaum et al.,
2009). Agonist binding is thought to induce distinct conforma-Ctional changes that enable GPCRs to couple to and activate
specific heterotrimeric G proteins (Oldham and Hamm, 2008).
For example, 2AR is a Gq-coupled GPCR that responds to the
neurotransmitter serotonin (5-HT) (Gonza´lez-Maeso and Seal-
fon, 2009), andmGluR2 is aGi-coupled, pertussis toxin-sensitive
GPCR that responds to the neurotransmitter glutamate (Glu)
(Moreno et al., 2009). Although considerable biochemical and
biophysical data are consistent with monomeric GPCRs binding
and activating G proteins (Ernst et al., 2007; Whorton et al.,
2007), several recent studies suggest that G protein coupling
in cell membranes involves the formation of homomeric and het-
eromeric GPCR complexes (Han et al., 2009; Lopez-Gimenez
et al., 2007; Carriba et al., 2008; Vilardaga et al., 2008). Oligo-
meric receptor complexes appear to exhibit distinct signaling
properties when compared to monomeric receptors (Urizar
et al., 2011; Milligan, 2009). The molecular mechanism(s)
responsible for such changes in pharmacology are poorly under-
stood, as is the physiological function of GPCR heteromeric
complexes.
Atypical antipsychotic drugs have a high affinity for the 2AR
(Meltzer et al., 1989; Meltzer and Huang, 2008) and are widely
used in the treatment of schizophrenia and other psychiatric
disorders (Ross et al., 2006). Interestingly, it has been recently
recognized that most clinically effective antipsychotic drugs
are, in fact, 2AR inverse agonists—ligands that preferentially
bind and stabilize a GPCR in an inactive conformational state
(Kenakin, 2002)—rather than simply neutral antagonists (Aloyo
et al., 2009; Egan et al., 1998; Weiner et al., 2001)—ligands
that compete for the same orthosteric binding site and prevent
the cellular responses induced by agonists and inverse agonists.
The mechanism underlying the antipsychotic effects of 2AR
inverse agonism has not yet been elucidated.
A new class of potential antipsychotic drugs acting as agonists
of mGluR2 recently received attention in preclinical (Woolleyell 147, 1011–1023, November 23, 2011 ª2011 Elsevier Inc. 1011
et al., 2008) and clinical studies (Patil et al., 2007, Kinon et al.,
2011). Previous work demonstrated that mGluR2 and 2AR
form a specific heterocomplex in mammalian brain tissue (Gon-
za´lez-Maeso et al., 2008; Rives et al., 2009). However, the
signaling properties of this receptor heterocomplex and its role
in transducing antipsychotic drug activity remain unclear. Here,
we compare G protein signaling coupled to the heteromeric
mGluR2/2AR complex with homomeric signaling through either
mGluR2 or 2AR. Our results provide insight into how Gi and Gq
signaling are integrated by this GPCR heteromer and uncover
a unifying mechanism of action of two families of antipsychotic
drugs that target themGluR2/2AR heteromeric complex. In addi-
tion, we provide a predictive metric for the anti- or propsychotic
effects of serotonergic and glutamatergic ligands.
RESULTS
Heteromeric Assembly of mGluR2 and 2AR Enhances
Glutamate-Elicited Gi Signaling and Reduces
5-HT-Elicited Gq Signaling
2AR andmGluR2 proteins colocalize inmouse cortical slices and
neuronal primary cultures (Figure 1A and Figure S1E available
online). In addition, the two receptors can be coimmunoprecipi-
tated from mouse frontal cortex (Figure 1B). To investigate the
signaling properties of the mGluR2/2AR heterocomplex, we
utilized a Xenopus oocyte heterologous expression system
(Barela et al., 2006). We expressed each of these GPCRs alone
or together and used inhibition of the IRK3 (Kir2.3) current to
monitor 2AR-elicited Gq activity (Figure 1C, left) (Du et al.,
2004) and activation of the GIRK4* (or Kir3.4*) current to monitor
mGluR2-elicited Gi activity (Figure 1C, right) (He et al., 1999,
2002) (see Experimental Procedures).
How do the signaling properties of the mGluR2/2AR hetero-
meric complex differ from those of the homomeric receptors?
We first quantified the Gi and Gq activities evoked by Glu and
5-HT, the endogenous ligands of the mGluR2 and 2AR recep-
tors, respectively, and compared these values to Gi and Gq
activities in the absence or presence of the heteromeric receptor
partner (Figures 1C–1E). Coexpression of mGluR2 with the 2AR
reduced 5-HT-elicited Gq activity by approximately 50%
(Figures 1C, left panel and 1D). In contrast, coexpression of
mGluR2 with the 2AR increased the Glu-elicited Gi activity by
nearly 200% (Figure 1C, right panel and 1E).
The metabotropic glutamate receptor 3 (mGluR3), which
shares a high degree of homology with mGluR2, does not form
a receptor heterocomplex with the 2AR. Exchanging the trans-
membrane (TM) domains of mGluR2 and mGluR3 either disrupts
(mGluR2D) or rescues (mGluR3D) mGluR2/2AR receptor com-
plex formation and 2AR-mediated cross-signaling (i.e., Gi sig-
naling) (Gonza´lez-Maeso et al., 2008). mGluR2D activation does
not evoke the Gi and Gq signaling outputs associated with the
mGluR2/2AR heteromer, whereas mGluR3D activation induces
an increase in Gi- and decrease in Gq-dependent signaling
(Figures S1A–S1D). Each of the mGluR chimeras, when ex-
pressed as homomers, showed intact Gi signaling (Figures
S2A–S2C) and cell-surface localization (Figure S2D). Together
these findings suggest that the heteromeric receptor couples Gi
and Gq outputs to influence downstream signaling events.1012 Cell 147, 1011–1023, November 23, 2011 ª2011 Elsevier Inc.To summarize the difference between Gi and Gq signaling
evoked by the mGluR2/2AR heteromers, we developed a metric
called the balance index (BI). The BI combines the change in
Gi activity (DGi) and the change in Gq activity (DGq), such that
BI = DGi  DGq (Figure 1F). We used homomeric Gi and Gq
signaling levels to normalize the data and found that without
stimulation, the mGluR2/2AR complex yielded a BI of 1.45,
which we use as the reference BI level (BIr). We obtained the
largest BIr when expressing mGluR2/2AR mRNAs in a 1:2 ratio
(Figure S3D). As shown in Figure S3C, this ratio of mRNAs
yielded a cell-surface localization of receptor protein levels that
suggested a higher-order oligomeric complex between mGluR2
and 2AR (see Figures S3A and S3B).
Drugs that Bind 2AR Alter the Balance between Gi
and Gq Signaling
We next asked whether drugs bound to one receptor of the
heteromer could affect the other receptor’s signaling response
to its endogenous ligand. We first investigated the effects of
2AR ligands (a neutral antagonist, a strong agonist, and an
inverse agonist) on Glu-elicited Gi signaling by mGluR2. We
define DOI as a strong agonist because it evokes greater Gq sig-
naling through 2AR than the endogenous ligand, 5-HT (Figures
2A, 2B, and S4A). In control experiments, the strong agonist
(DOI), the neutral antagonist (methysergide), and the inverse
agonist (clozapine) (Weiner et al., 2001) worked as expected to
stimulate or reduce 5-HT-induced Gq signaling, respectively
(Figure 2A).
Occupancy of the 2AR by either methysergide, DOI, or cloza-
pine had different effects on Glu-elicited signaling through
mGluR2 (Figure 2B, blue bars). Although Glu-elicited Gi sig-
naling was not altered by 5-HT or methysergide, it was de-
creased back to baseline by DOI and increased by approxi-
mately 40% (240% greater than homomeric levels) by clozapine
(Figure 2B).
Using the results obtained for Gi (Figure 2B, blue bars) and Gq
signaling (Figures 2A and 2B, red bars), we calculated the BI
values for the three ligands in the presence of the endogenous
ligands (Figure 2C). The changes evoked by these three drugs
were abrogated by mGluR2D or mimicked by mGluR3D (see
Table S1), and they were present when the Gq pathway was
blocked by the regulator of G protein signaling subunit 2
(RGS2) (Figures S5D and S5E). The 2AR ligand with the largest
overall BI was the inverse agonist clozapine (BI = 2.30; 140%
increase in Gi and 100% decrease in Gq).
Could these ligands exert their effects by stabilizing different
conformations of the receptor complex? To address this ques-
tion, we investigated the conformational changes induced by
the three 2AR ligands in molecular models of 2AR alone or com-
plexed with mGluR2. To observe large conformational changes
in relatively short timescales, we used a combination of adia-
batic-biased molecular dynamics (ABMD) and metadynamics
simulations (see ‘‘Computational Methods’’ in Experimental
Procedures). This approach was recently validated on a proto-
typic GPCR (Provasi et al., 2011). First, we studied the effects
of methysergide, DOI, and clozapine on the activation free-
energy profile of a protomeric 2AR (see Figure 2D, top) and iden-
tified the most energetically favorable 2AR state for each ligand.
Figure 1. Heteromeric Assembly of 2AR and mGluR2 Enhances Glu-Induced Gi Signaling and Reduces 5-HT-Induced Gq Signaling
(A) Representative micrographs showing coexpression of endogenous 2AR (red) and mGluR2 (green) in mouse frontal cortex (left panels) and mouse cortical
primary neurons (right panels). Scale bar, 25 mm. See also Figure S1E. 2AR and mGlu2 colocalize and form a receptor complex in mouse frontal cortex.
(B) Mouse frontal cortex membrane preparations were immunoprecipitated (IP) with anti-2AR antibody. Immunoprecipitates were analyzed by western blot (WB)
with anti-mGluR2 antibody (lower blot). Mouse frontal cortex membrane preparations were also directly analyzed by WB with anti-2AR antibody (upper blot) or
anti-mGluR2 antibody (middle blot). 2AR-KO and mGluR2-KO mouse frontal cortex tissue samples were processed identically and used as negative controls.
Frontal cortex tissue samples from 2AR-KO and mGluR2-KO mice were also homogenized together (mixed) and processed identically for immunoprecipitation
and WB.
(C) Representative barium-sensitive traces of IRK3 currents obtained in response to 1 mM 5-HT in oocytes expressing 2AR alone, mGluR2 and 2AR together, or
mGluR2 alone (left). Representative barium-sensitive traces of GIRK4* currents obtained in response to 1 mMGlu in oocytes expressing mGluR2 alone, mGluR2
and 2AR together, or 2AR alone (right). Barium (Ba) inhibited IRK3 and GIRK4* currents and allowed for subtraction of IRK3- and GIRK4*-independent currents.
For illustrative purposes, traces with similar basal currents were chosen.
Summary bar graphs of (D) Gq activity measured as IRK3 current inhibition (mean ± standard error of the mean [SEM]) following stimulation with 5-HT and (E) Gi
activity measured as GIRK4* current activation (mean ± SEM) following stimulation with Glu. IRK3 current inhibition was measured relative to basal currents and
was normalized relative to that obtained by stimulating 2AR alone with 5-HT (100% or 1). GIRK4* current activation was measured relative to the basal currents
and was normalized relative to that obtained by stimulating mGluR2 alone with Glu (100% or 1).
(F) Calculation of the BI as the difference of the increase in Gi signaling in response to Glu from the mGluR2 homomeric level (DGi) and the decrease of Gq
signaling in response to 5-HT from the 2AR homomeric level (DGq). A reference BI (Bir = 1.45) was calculated for the mGluR2/2AR complex in response to 1 mM
Glu and 1 mM 5-HT using mean values (**p < 0.01, ***p < 0.001). Error bars depict standard error of the mean (SEM).
See also Figures S1, S2, and S3.In agreement with known efficacies of these ligands, the cloza-
pine-bound 2AR conformation is inactive (i.e., 2RH1-like), the
DOI-bound 2AR conformation is active (i.e., 3P0G-like), and
the methysergide-bound conformation adopts an inactive stateCthat is structurally different from the inactive state stabilized by
clozapine.
To provide a structural context for the crosstalk between
2AR and mGluR2, we studied the effects of the three 2ARell 147, 1011–1023, November 23, 2011 ª2011 Elsevier Inc. 1013
Figure 2. Drugs that Target 2AR: Integrative Effects on Gi and Gq Signaling
(A) SummarybargraphsofGi activity (mean±SEM)measured in oocytesexpressingmGluR2/2AR following stimulationwith1mM5-HTaloneor togetherwith10mM
methysergide, 10 mMDOI, or 10 mM clozapine. Gq activity was normalized relative to that obtained by stimulation of 2AR alone with 5-HT (100% or 1, dotted line).
(B) Summary bar graphs of Gi activity (top) and Gq activity (bottom) (mean ± SEM) measured in oocytes expressing mGluR2/2AR following stimulation with 1 mM
Glu alone or together with 10 mM methysergide, 10 mM DOI, or 10 mM clozapine. Gi and Gq activity was normalized relative to the response to Glu and 5-HT,
respectively (100% or 1, dotted line).
(C) DGi referenced to the homomeric mGluR2 response to 1 mM Glu and DGq referenced to the homomeric 2AR response to 1 mM 5-HT together with 10 mM
methysergide, 10 mM DOI, or 10 mM clozapine (**p < 0.01, ***p < 0.01, n.s.: not significant). Data are mean ± SEM.
(D) Metadynamics-based mechanistic interpretation of functional crosstalk between 2AR and mGluR2. (Top) Activation profile of 2AR in the presence of different
ligands. Free energy of the 2AR bound to the inverse agonist clozapine (green), the neutral antagonist methysergide (purple), and the dominant agonist DOI
(orange), as a function of the position along the path connecting the inactive (s = 1) to the active (s = 8) states, is shown. (Bottom) Activation profile ofmGluR2 in the
presence of the different ligand-specific 2AR conformations. The three lines correspond to the activation free-energy profile of mGluR2 in dimeric complex
through a TM4-TM4 interface with 2AR bound to the inverse agonist clozapine (green line), a TM4,5-TM4,5 interface with 2AR bound to the neutral antagonist
methysergide (purple), and a TM4,5-TM4,5 interface with 2AR bound to the dominant agonist DOI (orange line). Themost energetically stable states are indicated
by a star, and the chemical structures of the three drugs are also shown.ligands on mGluR2 conformations in the dimeric complex. Fig-
ure 2D (bottom) shows that when clozapine is bound to 2AR,
the mGluR2 equilibrium shifts toward an activated conformation
(i.e., 3DBQ-like), consistent with functional upmodulation of Gi
signaling. In contrast, when methysergide and DOI are bound to
2AR, mGluR2 is stabilized in inactive states (i.e., 1U19-like).
Although no significant energetic and structural differences
were noted between the TM regions of these inactive states,
the functional downmodulation of Gi signaling induced by DOI,
but notbymethysergide,maybeascribed todifferent interactions
between the receptor loop regions and the G protein, which are1014 Cell 147, 1011–1023, November 23, 2011 ª2011 Elsevier Inc.not taken into account in our simulations. The functional predic-
tions from this computational approach can be used to guide
structure-based rational discovery of novel ‘‘biased’’ drugs that
are capable of selectively activating specific signaling pathways.
Together, these results indicate that formation of the hetero-
mer enables modulation of the mGluR2-Gi response by 2AR
ligands. Whereas drugs such as the strong 2AR agonist DOI
can greatly stimulate Gq signaling and decrease Gi signaling
(henceforth referred to as dominant agonists), inverse agonists,
such as clozapine, have the opposite effect, abolishing Gq and
increasing Gi signaling.
Figure 3. Drugs that Target mGluR2: Integrative Effects on Gi and Gq Signaling
(A) Summary bar graphs of Gi activity (mean ± SEM) measured in oocytes expressing mGluR2/2AR following stimulation with 1 mM Glu alone or together with
10 mM eGlu, 10 mM LY37, or 10 mM LY34. Gi activity was normalized relative to that obtained by stimulation of mGluR2 alone with 5-HT (100% or 1, dotted line).
(B) Summary bar graphs of Gq activity (red) and Gi activity (blue) (mean ± SEM) measured in oocytes expressing mGluR2/2AR following stimulation with 1 mM
5-HT alone or together with 10 mM eGlu, 10 mM LY37, or 10 mMLY34. Gq and Gi activities were normalized relative to the response to 5-HT and Glu, respectively
(100% or 1, dotted line).
(C) DGi referenced to the homomeric mGluR2 response to 1 mM Glu and DGq referenced to the homomeric 2AR response to 1 mM 5-HT together with 10 mM
methysergide, 10 mM DOI, or 10 mM clozapine (**p < 0.01, ***p < 0.01, n.s.: not significant). Data are mean ± SEM.
See also Figures S4 and S5.Drugs that Bind mGluR2 Alter the Balance between Gi
and Gq Signaling
How do drugs bound to the mGluR2 component of the hetero-
mer affect the 5-HT-elicited Gq signaling of the 2AR? Neutral
antagonist ethylglutamic acid (eGlu), the strong agonist (LY37)
(Figure S4B), and the inverse agonist (LY34) (Figure S4C) worked
as expected to reduce, stimulate, or abolish Glu-elicited Gi
signaling through mGluR2, respectively (Figure 3A). Consistent
with its inverse-agonist properties, LY34 not only completely
abolished Gi signaling but also reduced the basal Gi activity of
the mGluR2 receptor even in the absence of Glu (Figure S4C).
Occupancy of the mGluR2 receptor by each of the three
ligands influenced the 2AR signaling. Relative to the homomeric
2AR levels, formation of the complex reduced the extent of
Gq signaling by 50% (Figures 3B, 1D, and 1F). Although 5-HT-eli-
cited Gq signaling was unaffected by Glu or eGlu, it was further
decreased by LY37 and restored to near-homomeric levels by
LY34 (Figure 3B).CUsing the data shown for Gi (Figures 3A and 3B, blue bars) and
Gq signaling (Figure 3B, red bars), we calculated the BI values for
the three ligands (Figure 3C). Aswith 2ARdrugs, the neutral antag-
onist eGlu only affected the mGluR2 side of signaling. The strong
agonist LY37, however, affected both types of signaling through
the complex and showed a dominant-agonist behavior as defined
previously. Furthermore, LY37, like DOI, cross-signaled and eli-
cited Gq signaling in the absence of Glu and 5-HT, respectively
(FiguresS4F andS4G). The inverse agonist LY34 had the opposite
two effects: it blocked Gi but also potentiated Gq signaling,
achieving almost 2AR homomeric levels (83%). All effects were
disrupted when replacing mGluR2 by mGluR2D or rescued by
mGluR3D (see Table S1), and they were present when the Gi
pathway was blocked by pertussis toxin (PTX) (Figures S5A–
S5C). The largest overall signaling difference between Gi and Gq
was obtained by the dominant agonist LY37 (BI = 2.10).
In summary, the formation of the heteromeric complex favors
Gi over Gq signaling by endogenous ligands. Dominant agonistsell 147, 1011–1023, November 23, 2011 ª2011 Elsevier Inc. 1015
Figure 4. Use of BI to Classify Anti-/Propsychotic Propensity of
Drugs Targeting the mGluR2/2AR Complex
Correlation maps between the BI and percentage of Gi-Gq balance loss or
recovery for different drugs assuming a fractional occupancy of the heteromer
by the drug of 0.5 (see Experimental Procedures). BIs were calculated for
10 mM (BI10) (A) and 50 mM (BI50) (B) concentrations of the drugs together with
1 mM Glu and 1 mM 5-HT and placed accordingly in the horizontal axis. BIr =
1.45 corresponds to zero. Effects on the difference between Gi and Gq
signaling are shown for drugs with known antipsychotic effects like clozapine,
risperidone, and LY37, for ritanserin, an antidepressant, for neutral antagonists
methysergide and eGlu, for the psychedelic DOI, and for the propsychotic
LY34 (see also Table S1). Error bars depict SEM.enhance signaling through the receptor they target as part of the
complex but inhibit signaling of the heteromeric receptor
partner. Inverse agonists inhibit signaling through the receptor
they target as part of the complex but enhance signaling of the
heteromeric receptor partner.
The BI Predicts the Anti- or Propsychotic Activity
of Drugs Targeting mGluR2 or 2AR
Our results in Figures 2 and 3 indicate that although clozapine
and LY37 act on different receptors, both drugs act through1016 Cell 147, 1011–1023, November 23, 2011 ª2011 Elsevier Inc.the mGluR2/2AR complex to achieve a similar effect—an
increase in Gi activity with a concomitant decrease in Gq activity.
To test whether the psychoactive effects of specific drugs corre-
lated with differences in the levels of Gi and Gq activity that they
induced, we calculated BI values for multiple drugs. For mGluR2,
in addition to the dominant agonist LY37, we tested the neutral
antagonist eGlu and the inverse agonist LY34, a drug that has
been shown to increase locomotor activity and exploratory
behavior in mice and might be propsychotic (Bespalov et al.,
2007). For 2AR, besides the inverse agonist clozapine, we tested
the following: risperidone, another widely used atypical antipsy-
chotic like clozapine; ritanserin, an antidepressant also used
as an adjuvant therapeutic for schizophrenia; methysergide,
a neutral antagonist mainly used for migraines; and DOI, a prop-
sychotic drug with lysergic acid diethylamide (LSD)-like effects.
In the presence of endogenous ligands and absence of drugs,
the difference between Gi and Gq signaling is naturally kept in
a balance that favors Gi over Gq (BIr). We set the reference level
of the BI scale to BIr = 1.45 and compared the relative effect of
different drugs on the BI, assuming a 50% occupancy of the
receptor by the drug (see Gi-Gq recovery/loss calculation in
Experimental Procedures). Results from drugs that target
mGluR2 (blue icons), versus those that target 2AR (red icons),
are plotted in Figure 4.
Drugs with the most effective antipsychotic properties,
regardless of the receptor they target (2AR: clozapine, risperi-
done; mGluR2: LY37), show the highest BI values. In contrast,
drugs with the most effective propsychotic properties (2AR:
DOI; mGluR2: LY34) show the lowest BI values (Figure 4 and
Table S2). All of these drugs are either dominant agonists (anti-
psychotic for mGluR2 and propsychotic for 2AR) or inverse
agonists (antipsychotic for 2AR and propsychotic for mGluR2).
Inverse-Agonist Upmodulation Occurs in Mouse Frontal
Cortex
To study the relevance of mGluR2/2AR heteromer signaling
in vivo, we examined the pattern of G protein coupling in mouse
frontal cortex, a region that plays an important role in schizo-
phrenia and antipsychotic action (Gonza´lez-Maeso and Sealfon,
2009). We first measured the mGluR2/2AR complex-dependent
upmodulation of Gi signaling by a 2AR inverse agonist.
Membrane preparations from mouse frontal cortex were incu-
batedwith the inverse agonist clozapine or the neutral antagonist
methysergide (Figures S4D and S4E), together with DCG-IV,
a selective mGluR2/3 agonist. Clozapine increased the DCG-
IV-mediated Gi signaling (Figure 5A), whereas methysergide
did not significantly affect Gi signaling (Figure 5B). Furthermore,
clozapine failed to increase the DCG-IV-mediated Gi signaling in
frontal cortex membrane preparations from 2AR knockout (KO,
Htr2a/) mice (Figure S6C; see also Figures S6A and S6B for
LY37-dependent activation of Gq in wild-type but not in
2AR-KO mouse frontal cortex).
We also tested the mGluR2 inverse-agonist upmodulation of
Gq signaling in cortical primary cultures. Stimulation of Gq
signaling in neurons is known to elicit a transient increase of
intracellular calcium via an IP3-mediated Ca
2+ release from the
endoplasmic reticulum (ER) that can be recorded using fluores-
cent calcium-sensitive dyes (Pichon et al., 2010). As predicted,
Figure 5. Upmodulation of Gq Signaling by LY34 and Gi Signaling by Clozapine in Mouse Frontal Cortex
DCG IV-stimulated [35S]GTPgS binding in mouse frontal cortex membranes followed by immunoprecipitation with anti-Gai antibody in the presence of clozapine
(A), methysergide (B), or vehicle. Activation of Gi was accomplished by DCG IV (10 mM). Data represent mean ± SEM (*p < 0.05, **p < 0.01, ***p < 0.001, n.s.: not
significant) (see also Figure S6C).
(C) Representative traces of 5-HT-evoked elevation of intracellular calcium in mouse cortical neurons as detected by ratiometric Fura-2 measurements.
Measurements were obtained with 200 mM LY34 alone, 100 mM 5-HT (5-HT) alone, 100 mM 5-HT together with 200 mM eGlu (mGluR2 neutral antagonist), and
100 mM 5-HT together with 200 mM LY34 (mGluR2 inverse agonist).
(D) Bar graph summary of measured Fura-2 R340/380 change. Traces were normalized to the basal level, the steady-state fluorescence before perfusion of drugs.
Data are mean ± SEM (*p < 0.05, ***p < 0.001, n.s.: not significant).
(E) Summary bar graphs (mean ± SEM) of the total MK801-induced locomotion as a summation of horizontal activity from t = 30 min to t = 120 min. Injection time
was at t = 0 min. Wild-type (WT, left) and 2AR-KO (right) mice were administered LY37 (5 mg/kg) or vehicle, followed by MK801 (0.5 mg/kg) or vehicle (N = 5–6).
(F) Wild-type mice were administered clozapine (1.5 mg/kg) or vehicle, followed by MK801 (0.5 mg/kg) or vehicle (left). mGluR2-KO mice were administered
clozapine (1.5 mg/kg) or vehicle (right) (*p < 0.05, **p < 0.01, ***p < 0.001, n.s.: not significant).LY34 was able to boost the 5-HT response nearly 5-fold (Figures
5C and 5D) but showed no response alone. In contrast, coappli-
cation of the mGluR2 neutral antagonist eGlu with 5-HT did not
elicit a significant increase in intracellular calcium (Figures 5C
and 5D).
These data provide evidence that the effects of inverse
agonists that bind 2AR or mGluR2 and boost their heteromeric
partner receptor’s signaling occur in cortical neurons in vivo
(Figures 5A–5D).
2AR and mGluR2 Are Both Necessary for Antipsychotic-
like Behavior in Mice
How do the antipsychotic drugs LY37 and clozapine influence
behaviors? We determined the effects of the mGluR2/3 agonist
LY37 on locomotor behavior precipitated by treatment with
MK801 (Figure 5E). Noncompetitive NMDA receptor antago-
nists, such as phencyclidine (PCP) and ketamine, are used to
model schizophrenia in rodents because of their capacity toCevoke human behaviors similar to those observed in patients
(Morris et al., 2005; Mouri et al., 2007; Patil et al., 2007). The
potent and selective noncompetitive NMDA receptor antagonist
MK801 (dizocilpine) can also elicit similar symptoms (Reimherr
et al., 1986). Activation of mGluR2, but not mGluR3, by LY37
has been shown to reduce hyperlocomotion induced by
noncompetitive NMDA antagonists in mouse models of schizo-
phrenia (Woolley et al., 2008). MK801-stimulated locomotor
activity in wild-type and 2AR-KO mice was indistinguishable.
MK801-stimulated activity was significantly attenuated by
LY37 in wild-type mice, but not in 2AR-KO (Htr2a/) or
mGluR2-KO (Grm2/) mice (Figures 5E and S7B).
We next tested the role of mGluR2 in the antipsychotic-like
effect induced by the atypical antipsychotic clozapine. Because
clozapine binds with high affinity to 2ARs, and with lower affinity
to dopamine D2 receptors (Meltzer et al., 1989), we first estab-
lished the lowest dose of clozapine that induced an antipsy-
chotic-like effect in mice (Figure S7A). The locomotor activityell 147, 1011–1023, November 23, 2011 ª2011 Elsevier Inc. 1017
Figure 6. Control of BI through a Drug Combination Approach
(A) BI calculations at 50 mMconcentrations of ligands. DGi referenced to the homomeric mGluR2 (1 ng of mRNA) response to 1 mMGlu and DGq referenced to the
homomeric 2AR (2 ng of RNA) response to 1 mM 5-HT and 1 mM Glu. Responses to a concentration of 50 mM clozapine, LY37, or LY37 together with clozapine
were measured in oocytes injected with 1 ng mGluR2 mRNA and 1 ng (left), 2 ng (center), and 3 ng (right) 2AR mRNA, respectively. Data are mean ± SEM.
(B) Summary bar graphs (mean ± SEM) of the total MK801-induced locomotion as a summation of horizontal activity from t = 30 min to t = 120 min. Injection time
was at t = 0min. mGluR2 heterozygotes (mGluR2+/) (left) and 2AR heterozygotes (right) are shown. Mice were administered vehicle, clozapine (1.5 mg/kg), LY37
(5 mg/kg), or both LY37 and clozapine, followed by MK801 (0.5 mg/kg) (N = 5–6). (*p < 0.05, n.s.: not significant).induced by MK801 was similar in wild-type and mGluR2-KO
mice. Notably, pretreatment with 1.5 mg/kg clozapine signifi-
cantly decreased the MK801-stimulated locomotion in wild-
type mice but not mGluR2-KO mice (Figure 5F), and this treat-
ment hadnoeffect on 2AR-KOmice (FigureS7C; seealsoFigures
S7A–S7C). Although our results are consistent with the absence
of antipsychotic-like behavioral effects of methysergide (com-
pare Figure 5F for clozapine with Figures S7D and S7E for meth-
ysergide), they do not exclude the possibility that the absence of
antipsychotic-like effects of LY37 in 2AR-KOmay be affected by
the lower expression of mGluR2 in 2AR-KO mice (Gonza´lez-
Maeso et al., 2008; Moreno et al., 2011). Coinjection of LY37
and clozapine (1.5 mg/kg) did not affect the MK801-dependent
locomotor response in either mGluR2-KO or 2AR-KO mice
(data not shown). Together, these findings demonstrate that the
mGluR2-dependent antipsychotic-like behavioral response of
LY37 requires the expression of the 2AR, and that the corre-
sponding 2AR-dependent effect of clozapine requires the ex-
pression of mGluR2.
A Drug Combination Approach to Control Psychotic-like
Behavior
Recent preclinical findings suggest that coadministration of
suboptimal doses of atypical and Glu antipsychotics results in1018 Cell 147, 1011–1023, November 23, 2011 ª2011 Elsevier Inc.robust therapeutic-like behavioral effects and reduced
unwanted side effects (Uslaner et al., 2009). We postulated
that alterations in 2AR and mGluR2 expression levels in our
system (Figures 1F and S3D) may model the alterations in 2AR
and mGluR2 ratios observed in postmortem brain samples
from untreated schizophrenic patients (Gonza´lez-Maeso et al.,
2008). We asked whether coadministration of clozapine (a 2AR
inverse agonist) with LY37 (a mGluR2 dominant agonist)
compensates for alterations in Gi-Gq balance caused by subop-
timal expression ratios of the two receptors. To this end, we in-
jected clozapine with LY37 and determined the BI. Figure 6A
shows the DGi and DGq values obtained in response to cloza-
pine, LY37, and LY37 together with clozapine. Coadministration
of the two drugs increased significantly the BI in both suboptimal
cases (left and right panels) compared to the optimal case
(middle panel). These results reveal that coadministration of
LY37 and clozapine can compensate for the loss in signaling
capacity that is likely to result from decreased mGluR2/2AR het-
eromeric formation, as cross-signaling is decreased in subop-
timal signaling receptor ratios.
Behavioral experiments showed that administration of
either clozapine or LY37 in mGluR2 or 2AR heterozygote
mice did not affect the MK801-dependent locomotor response
(Figure 6B). However, coadministration of both antipsychotics
Figure 7. Gi-Gq Balance Model of the Mechanism of Action of Antipsychotic and Psychedelic Drugs through the mGluR2/2AR Complex
Formation of the receptor complex establishes an optimal Gi-Gq balance in response to Glu and 5-HT (increase in Gi, decrease in Gq).
(A) Psychedelics (LY34 and DOI) invert the balance (strong Gi decrease, strong Gq increase).
(B) Disruption of the optimal balance in psychotic states (decrease in Gi, increase in Gq) can be compensated for by antipsychotics (LY37, clozapine, and
risperidone) that recover the Gi-Gq balance (increasing Gi and decreasing Gq).in mGluR2 or 2AR heterozygotes significantly decreased the
MK801-stimulated locomotor activity (Figure 6B). These results
suggest that a combination of mGluR2 dominant agonists with
2AR inverse agonists is likely to synergize in vivo to achieve an
optimal signaling ratio in cases where a suboptimal Gi-Gq
signaling balance exists.
DISCUSSION
Previous work demonstrated that mGluR2 and 2AR form a func-
tional heteromeric complex through which hallucinogenic drugs
cross-signal to the Gi-coupled receptor (Gonza´lez-Maeso et al.,
2008). It was not clear how the heteromeric complex signaled in
response to ligands binding to either receptor and whether the
differential pharmacology of this GPCR heteromer could be
considered widely as a tractable therapeutic target for psychotic
behavior. Our current study indicates that the mGluR2/2AR het-
eromer establishes a Gi-Gq balance in response to endogenous
ligands (e.g., Glu and 5-HT). We utilized a simple metric, the BI,
that quantifies the change in Gi (increase) and Gq (decrease)
signaling upon heteromerization relative to the homomeric
signaling levels.
The BI can be modulated either by dominant agonists that
take control over their counterpart receptors or by inverse
agonists that lift this control. This establishes a map between
the ligand input to the heteromer (e.g., agonist/agonist, dominant
agonist/agonist, neutral antagonist/agonist, inverse agonist/
agonist) and its signaling output in terms of how specific ligands
affect the BI. Our results are in agreement with results from
a GPCR complex of D2 receptor homomers coupled to a single
Gi protein subunit (Han et al., 2009). Our study further extendsCthese previous findings and demonstrates a signaling crosstalk
between the 2AR and mGluR2, which are individually coupled
to two different subtypes of G proteins (Gq andGi). Our data indi-
cate that signaling crosstalk through the mGluR2/2AR hetero-
complex may be a causal mechanism for the induction of cellular
and behavioral responses that differ from those of mGluR2 and
2AR homomers.
In our model (Figure 7), psychedelics invert the signaling
balance through the complex (Gi signaling decreases, whereas
Gq signaling increases, thus decreasing the BI), tipping the
balance from being in favor of Gi signaling (normal complex) to
being in favor of Gq signaling (propsychotic) (Figure 7A). Simi-
larly, disease states involving psychosis, such as schizophrenia,
would be expected to be associated with a variable disruption of
the Gi-Gq balance (i.e., decrease in Gi, increase in Gq, and
decrease in BI) (Figure 7B), consistent with the mGluR2 downre-
gulation and 2AR upregulation observed in untreated schizo-
phrenic patients (Gonza´lez-Maeso et al., 2008). Such disruption
would be reversed by antipsychotics that recover the Gi-Gq
balance again in favor of Gi as in the normal complex (i.e.,
increasing Gi and decreasing Gq, thus increasing the BI) (Fig-
ure 7B). Because the Gi-Gq balance is the regulated variable
predicting psychotic state, it is not surprising that inverse
agonists on the 2AR side and strong agonists on the mGluR2
side are the most effective antipsychotics. The present study
also suggests a unifyingmechanism of action of atypical antipsy-
chotics and the new glutamate antipsychotics. Our findings
suggest inverse agonism as a common feature of 2AR ligands
with antipsychotic properties. We show that dysregulation of
an optimal ratio of mGluR2 to 2AR expression via injection of
different mRNA ratios greatly decreases BI values, and singleell 147, 1011–1023, November 23, 2011 ª2011 Elsevier Inc. 1019
application of 2AR inverse agonists or mGluR2 dominant
agonists may not push the BI into the therapeutic range (see
Figure 4). Yet coadministration of the most effective mGluR2
and2ARdrugs yieldsBI values in the therapeutic range (Figure 6).
These findings in heterologous systems were paralleled in vivo
using heterozygous mice for 2AR or mGluR2: coinjection of
both clozapine and LY37 was needed to decrease the MK801-
dependent locomotor activity. In some schizophrenic
patients, atypical antipsychotics produce complete remission
of psychotic symptoms. However, two-thirds of schizophrenic
patients are considered treatment resistant, with persistent
psychotic and other symptoms despite the optimal use of avail-
able antipsychotic medications (Lieberman et al., 2005). The
absence of antipsychotic-like behavioral effect by injection of
either LY37 or clozapine in 2AR or mGluR2 heterozygous mice,
but not in the same mice coinjected with LY37 and clozapine,
points toward potential beneficial use of combination therapy
in treatment-resistant schizophrenia.
The metric (BI) that we provide allows quantification and
prediction of anti-/propsychotic effects of new drugs acting
through the mGluR2/2AR receptor heterocomplex. Although
long-term effects of drugs targeting mGluR2/2AR signaling are
not taken into account in the way we have estimated the BI
metric, the ability of this scale to predict appropriately the
most effective anti- and propsychotic drugs acting through the
receptor heterocomplex makes it a promising tool in predicting
the efficacy of new drugs. This metric, as well as structural
insights from ligand-specific heteromeric conformations, could
be used extensively for screening new compoundswith potential
antipsychotic effects.
Our results pave the way toward a new understanding of the
cellular signaling, function, and pharmacology of other hetero-
meric GPCRs that have been implicated as therapeutic targets
for the treatment of disease (Milligan, 2009). Provided that the
receptor complex signaling output can classify accurately the
behavior of drugs targeting the complex and used to treat
disease, the case of the mGluR2/2AR complex can serve as
a guiding example of development of therapeutic potency scales
that can be used to classify existing drugs and predict the
behavior of novel ones. Because the most effective antipsy-
chotic drugs targeting the mGluR2/2AR complex all gave the
highest BI values, it is likely that somehow signaling through
this complex is uniquely coupled to specific targets. The mech-
anism of such signaling specificity as well as the detailed actions
of Gi versus Gq signaling through the mGluR2/2AR complex,
aiming to achieve a homeostatic balance that ensures a normal
nonpsychotic state, are likely to become an active pursuit of
future studies.
EXPERIMENTAL PROCEDURES
Drugs, Molecular Constructs, Analysis of mGluR2 and 2AR Protein
Levels, and Surface Expression Assays
See Extended Experimental Procedures for details on all of these.
Expression of Recombinant Proteins in Xenopus Oocytes
Oocytes were isolated and microinjected with equal volumes (50 nl), as previ-
ously described (Lopes et al., 2002). In all two-electrode voltage-clamp exper-
iments (TEVC), oocytes were injected with 1 ng of mGluR2, 2 ng of1020 Cell 147, 1011–1023, November 23, 2011 ª2011 Elsevier Inc.mGluR2DTM4,5, 2 ng of mGluR3, 2 ng of mGluR3DTM4,5, 2 ng of 2AR, 2 ng
of GIRK4*, 2 ng of IRK3, 1 ng of PTX, or 4 ng of RGS2 and were maintained
at 18C for 1–4 days before recording.
TEVC Recording and Analysis
Whole-cell currents were measured by conventional TEVC with a GeneClamp
500 amplifier (Axon Instruments, Union City, CA, USA), as previously reported.
A high-potassium (HK) solution was used to superfuse oocytes (96 mM KCl,
1 mM NaCl, 1 mM MgCl2, 5 mM KOH/HEPES, pH 7.4) to obtain a reversal
potential for potassium (EK) close to zero.
Inwardly rectifying potassium currents through GIRK4* and IRK3 were ob-
tained by clamping the cells at 80 mV. In order to isolate Gi, GIRK4* was co-
injected with RGS2 in order to eliminate the Gq component in the current.
Basal IRK3 and GIRK4* currents were defined as the difference between
inward currents obtained at80mV in the presence of 3mMBaCl2 in HK solu-
tion and those in the absence of Ba2+ and measured for each trace. Current
inhibition and current activation were measured respectively and normalized
to basal current to compensate for size variability in oocytes.
Computational Methods
Molecular modeling: Because there are no available crystal structures of the
2AR or mGluR2 available to date, we generated initial molecular models of
these two receptors. Specifically, we built initial inactive conformations of
2AR or mGluR2 using a combination of homology modeling for the TM helices
and an ab initio loop prediction approach implemented in the Rosetta 2.2 code
(Wang et al., 2007) for the loop regions of the receptors. According to specific
structural and functional similarities, the b2-adrenergic (PDB 2RH1 (Cherezov
et al., 2007) or -rhodopsin (PDB 1U19 (Okada et al., 2004)) crystal structures
were used as structural templates for the homologymodeling of the TM regions
of 2AR or mGluR2, respectively. We generated activation pathways for each
receptor using the adiabatic-biased MD (ABMD) algorithm (Paci and Karplus,
1999) and a recently published simulation protocol (see Provasi et al., 2011 for
details). Free-energy values were calculated using a Monte Carlo scheme.
(see Extended Experimental Procedures for additional details.)
Experimental Animals
Experiments were performed on adult (8- to 12-week-old) male 129S6/SvEv
mice. 2AR-KO mice have been previously described (Gonza´lez-Maeso et al.,
2007). mGluR2-KO mice were obtained from the RIKEN BioResource Center,
Japan (see reference Yokoi et al., 1996 for details) and backcrossed for at least
ten generations onto a 129S6/SvEv background. All subjects were offspring of
heterozygote breeding. For experiments involving genetically modified mice,
2ARwild-type or mGluR2 wild-type littermates were used as controls. Animals
were housed for 12 hr light/dark cycles at 23Cwith food and water ad libitum.
The Institutional Animal Use and Care Committee approved all experimental
procedures at the Mount Sinai School of Medicine and Virginia Common-
wealth University.
Measurement of Intracellular Ca2+
Measurement of intracellular free calcium was performed as described in the
literature with minor modifications (Pichon et al., 2010) (see Extended Experi-
mental Procedures for details).
Coimmunoprecipitations and [3H]Ketanserin and [35S]GTPgS
Binding Assays
Mouse frontal cortex membrane preparations and binding assays were per-
formed as previously described with minor modifications (Gonza´lez-Maeso
et al., 2008) (see Extended Experimental Procedures for details).
Cortical Primary Cultures and Immunocytochemistry
Mouse cortical primary neurons were cultured as previously reported (Gonza´-
lez-Maeso et al., 2008).
(See Extended Experimental Procedures for details.)
Behavioral Studies
Locomotor and head-twitch behavioral studies were performed as previously
described (Gonza´lez-Maeso et al., 2008). Motor function was assessed with
a computerized three-dimensional activity monitoring system (AccuScanIn-
struments). The activity monitor has 32 infrared sensor pairs, with 16 along
each side spaced 2.5 cm apart. The system determines motor activity on
the basis of the frequency of interruptions to infrared beams traversing the x,
y, and z planes. Total distance (cm) traveled and vertical activity were deter-
mined automatically from the interruptions of beams in the horizontal and
vertical planes, respectively.
Calculation of Gi-Gq Balance Recovery and Loss
The total Gi-Gq balance achieved by the mGluR2/2AR heteromer in the pres-
ence of a drug was calculated with the following equation:
Total balance= x BId +BIrð1 xÞ
where x is the fraction of heteromer that binds the drug, BId is the balance
index of the drug at a fixed concentration, and BIr is the reference balance
index of the complex (1.45).
In the absence of drug (x = 0), the total balance achieved will be BIr (1.45). If
the drug has aBId = BIr, the total Gi-Gq balance is alsoBIr (1.45) for any fraction
x of drug-bound heteromer.
In a state where themGluR2/2AR heteromer is signaling at aBI < BIr (disease
state), a drug with a BId > BIr will be able to compensate for the total Gi-Gq
balance loss and reestablish a total balance of 1.45 (BIr), if BId is sufficiently
large.
The Gi-Gq balance recovery (R) was calculated with the following equation:
R= 100,

Total balance
BIr

 1

This value expressed as a percentage indicates the amount of Gi-Gq balance
that could be recovered by a drug with a balance index BId. It is determined by
the difference between the total balance achieved in the presence of the drug
compared to BIr. A positive Gi-Gq balance (total balance > BIr) indicates that
the drug is able to recover Gi-Gq balance (e.g., a drug with a BId of 2.3 with
a fractional occupancy x = 0.5 will have a total balance of 1.875, which will
allow recovery up to 30% loss from the reference level of 1.45). A negative
Gi-Gq balance (total balance < BIr) indicates that the drug induces a loss in
balance (e.g., a drug with a BId of 0.315 with a fractional occupancy x = 0.5
will have a total balance of 0.315, which will result in80% loss from the refer-
ence level of 1.45).
In order to compare drugs, we established an arbitrary reference level of
fractional occupancy of the heteromer by the drug (x = 0.5). This allowed
us to establish the differences in the ability of the drugs to recover or lose
the Gi-Gq balance based on their BI at equal conditions. Changes in the frac-
tional occupancy used for comparison (e.g., x = 0.25) changed the magni-
tude but not the relative order in the classification of the drugs shown in
Figure 4.
Statistical Methods
Statistical significance of behavioral experiments involving four groups and
two treatments was assessed by two-factor ANOVA followed by Bonferroni’s
post-hoc test. Statistical significance of behavioral experiments involving one
treatment was assessed by Student’s t test.
Each electrophysiological experiment in Xenopus oocytes was performed in
two batches. Every group in each experiment was tested in both batches. Data
for both batches were compiled (n = 8–16), and one-way ANOVA tests applied
followed by a multiple comparison procedure using Tukey’s honestly signifi-
cant difference test.
Intracellular calcium measurements were performed in three different isola-
tions. Data for all isolations were compiled (n = 7–11), and one-way ANOVA
tests applied followed by amultiple comparison procedure using Tukey’s hon-
estly significant difference test.
[3H]ketanserin binding experiments were performed 3–5 times in duplicate/
triplicate. A one-site model versus a two-site model, as a better description of
the data, was determined by F test. [35S]GTPgSbinding experiments were per-
formed three times in triplicate. Two-way ANOVA tests were applied to the
compiled data followed by a Bonferroni’s post-hoc test.CSUPPLEMENTAL INFORMATION
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